Project Grant R01AI191767
Award Date
7/21/25
Completion Date
6/30/30
Dollars Obligated
$1.1M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Oklahoma City, OK, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $1,144,714 to the University of Illinois to conduct research aimed at discovering novel antibiotics for gram-negative pathogens. The primary goals are to identify physicochemical traits that allow antibiotics to evade efflux pumps in E. coli, P. aeruginosa, and A. baumannii, and then apply this knowledge to develop at...
This federal Project Grant award of $254,478 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify mechanisms of resistance to pathogen-specific antibacterial antisense compounds and develop strategies to overcome them. The award recipient, The University of Texas Southwestern Medical Center, will investigate resistance to these novel antibacterial compounds called...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $241,500.00 to New York University (NYU) to develop a high-throughput screening approach to discover protein-based efflux pump inhibitors (EPIs) that can block antibiotic resistance in pathogenic bacteria. The goal is to establish a robust assay to rapidly identify EPIs, which are a promising class of therapeutics to...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) is focused on exploring synergistic combinations of aminoglycoside antibiotics to combat multidrug-resistant (MDR) gram-negative bacteria. The $475,036 award, granted on Apr 11, 2025, aims to: 1) Identify dual-aminoglycoside combinations that demonstrate synergistic and maximally suppressive activity against MDR bacterial isolates, while evaluating...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop new antimicrobial agents and combination therapies to combat the growing threat of Gram-negative bacterial pathogens, specifically carbapenem-resistant Acinetobacter baumannii (CRAB) and Klebsiella pneumoniae (CRKP). The $2,308,174 award, with a performance period from August 2024 to May 2029, will fund three...
This Project Grant award, ID R01AI175440, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $728,695 grant, awarded on Sep 1, 2024, will fund research at the University of Arkansas for Medical Sciences (UAMS) to investigate mechanisms of antibiotic resistance and heteroresistance to the novel cephalosporin antibiotic cefiderocol in carbapenem-resistant Gram-negative pathogens. The...
This Project Grant award of $747,763 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports the development of small molecule inhibitors of the LPXH enzyme as novel antibiotics to treat multidrug-resistant Enterobacterales infections. The goal is to design and synthesize potent LPXH inhibitors with optimal drug-like properties, and demonstrate the safety and efficacy of a lead LPXH inhibitor candidate in a murine sepsis...
This $811,396 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases under CFDA 93.855 Allergy and Infectious Diseases Research, is focused on understanding the mechanisms of lipid/metabolite and drug transport in Mycobacterium tuberculosis and related mycobacteria. The major objectives are to establish the molecular mechanisms and structures of three specific MMPL transporter proteins and their complexes with interacting partner proteins. Key activities include...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $392,747 to Oregon State University to investigate the biosynthesis and self-resistance mechanisms of the antibiotic compound kibdelomycin. The goals are to develop genetic systems to produce kibdelomycin variants and study the early biosynthetic steps, as well as investigate the self-resistance...
The federal Project Grant award R21AI190454 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Illinois. The $456,911 award, effective July 1, 2025 through June 30, 2027, supports research to develop innovative antibiotic combination therapies for treating hypervirulent, multidrug-resistant Klebsiella pneumoniae infections. Key objectives include elucidating the...